235 related articles for article (PubMed ID: 25132599)
1. Suppression of TDO-mediated tryptophan catabolism in glioblastoma cells by a steroid-responsive FKBP52-dependent pathway.
Ott M; Litzenburger UM; Rauschenbach KJ; Bunse L; Ochs K; Sahm F; Pusch S; Opitz CA; Blaes J; von Deimling A; Wick W; Platten M
Glia; 2015 Jan; 63(1):78-90. PubMed ID: 25132599
[TBL] [Abstract][Full Text] [Related]
2. Tryptophan-2,3-dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor-4.
Ochs K; Ott M; Rauschenbach KJ; Deumelandt K; Sahm F; Opitz CA; von Deimling A; Wick W; Platten M
J Neurochem; 2016 Mar; 136(6):1142-1154. PubMed ID: 26708701
[TBL] [Abstract][Full Text] [Related]
3. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
4. Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase.
Pilotte L; Larrieu P; Stroobant V; Colau D; Dolusic E; Frédérick R; De Plaen E; Uyttenhove C; Wouters J; Masereel B; Van den Eynde BJ
Proc Natl Acad Sci U S A; 2012 Feb; 109(7):2497-502. PubMed ID: 22308364
[TBL] [Abstract][Full Text] [Related]
5. The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma.
Sordillo PP; Sordillo LA; Helson L
Anticancer Res; 2017 May; 37(5):2159-2171. PubMed ID: 28476779
[TBL] [Abstract][Full Text] [Related]
6. Constitutive Expression of the Immunosuppressive Tryptophan Dioxygenase TDO2 in Glioblastoma Is Driven by the Transcription Factor C/EBPβ.
Kudo T; Prentzell MT; Mohapatra SR; Sahm F; Zhao Z; Grummt I; Wick W; Opitz CA; Platten M; Green EW
Front Immunol; 2020; 11():657. PubMed ID: 32477324
[TBL] [Abstract][Full Text] [Related]
7. The interplay between metabolic remodeling and immune regulation in glioblastoma.
Kesarwani P; Kant S; Prabhu A; Chinnaiyan P
Neuro Oncol; 2017 Oct; 19(10):1308-1315. PubMed ID: 28541512
[TBL] [Abstract][Full Text] [Related]
8. Antimicrobial and immunoregulatory properties of human tryptophan 2,3-dioxygenase.
Schmidt SK; Müller A; Heseler K; Woite C; Spekker K; MacKenzie CR; Däubener W
Eur J Immunol; 2009 Oct; 39(10):2755-64. PubMed ID: 19637229
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors.
Schramme F; Crosignani S; Frederix K; Hoffmann D; Pilotte L; Stroobant V; Preillon J; Driessens G; Van den Eynde BJ
Cancer Immunol Res; 2020 Jan; 8(1):32-45. PubMed ID: 31806638
[TBL] [Abstract][Full Text] [Related]
10. Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase?
Ren S; Correia MA
Arch Biochem Biophys; 2000 May; 377(1):195-203. PubMed ID: 10775460
[TBL] [Abstract][Full Text] [Related]
11. Delaying aging and the aging-associated decline in protein homeostasis by inhibition of tryptophan degradation.
van der Goot AT; Zhu W; Vázquez-Manrique RP; Seinstra RI; Dettmer K; Michels H; Farina F; Krijnen J; Melki R; Buijsman RC; Ruiz Silva M; Thijssen KL; Kema IP; Neri C; Oefner PJ; Nollen EA
Proc Natl Acad Sci U S A; 2012 Sep; 109(37):14912-7. PubMed ID: 22927396
[TBL] [Abstract][Full Text] [Related]
12. The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO).
Duhalde Vega M; Aparicio JL; Mandour MF; Retegui LA
Immunol Lett; 2020 Jan; 217():25-30. PubMed ID: 31726186
[TBL] [Abstract][Full Text] [Related]
13. The kynurenine pathway in brain tumor pathogenesis.
Adams S; Braidy N; Bessede A; Brew BJ; Grant R; Teo C; Guillemin GJ
Cancer Res; 2012 Nov; 72(22):5649-57. PubMed ID: 23144293
[TBL] [Abstract][Full Text] [Related]
14. High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes.
Seegers N; van Doornmalen AM; Uitdehaag JC; de Man J; Buijsman RC; Zaman GJ
J Biomol Screen; 2014 Oct; 19(9):1266-74. PubMed ID: 24870017
[TBL] [Abstract][Full Text] [Related]
15. Antitumour agents as inhibitors of tryptophan 2,3-dioxygenase.
Pantouris G; Mowat CG
Biochem Biophys Res Commun; 2014 Jan; 443(1):28-31. PubMed ID: 24269239
[TBL] [Abstract][Full Text] [Related]
16. Tryptophan 2,3-dioxygenase (TDO) inhibitors. 3-(2-(pyridyl)ethenyl)indoles as potential anticancer immunomodulators.
Dolusić E; Larrieu P; Moineaux L; Stroobant V; Pilotte L; Colau D; Pochet L; Van den Eynde B; Masereel B; Wouters J; Frédérick R
J Med Chem; 2011 Aug; 54(15):5320-34. PubMed ID: 21726069
[TBL] [Abstract][Full Text] [Related]
17. Tryptophan 2,3-Dioxygenase Expression Identified in Human Hepatocellular Carcinoma Cells and in Intratumoral Pericytes of Most Cancers.
Hoffmann D; Dvorakova T; Stroobant V; Bouzin C; Daumerie A; Solvay M; Klaessens S; Letellier MC; Renauld JC; van Baren N; Lelotte J; Marbaix E; Van den Eynde BJ
Cancer Immunol Res; 2020 Jan; 8(1):19-31. PubMed ID: 31806639
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure and mechanism of tryptophan 2,3-dioxygenase, a heme enzyme involved in tryptophan catabolism and in quinolinate biosynthesis.
Zhang Y; Kang SA; Mukherjee T; Bale S; Crane BR; Begley TP; Ealick SE
Biochemistry; 2007 Jan; 46(1):145-55. PubMed ID: 17198384
[TBL] [Abstract][Full Text] [Related]
19. Induction of tryptophan 2,3-dioxygenase in the mouse endometrium during implantation.
Tatsumi K; Higuchi T; Fujiwara H; Nakayama T; Egawa H; Itoh K; Fujii S; Fujita J
Biochem Biophys Res Commun; 2000 Jul; 274(1):166-70. PubMed ID: 10903913
[TBL] [Abstract][Full Text] [Related]
20. Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis.
Lanz TV; Williams SK; Stojic A; Iwantscheff S; Sonner JK; Grabitz C; Becker S; Böhler LI; Mohapatra SR; Sahm F; Küblbeck G; Nakamura T; Funakoshi H; Opitz CA; Wick W; Diem R; Platten M
Sci Rep; 2017 Jan; 7():41271. PubMed ID: 28117398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
